Bibliography
- LINDEN J: Cloned adenosine A3 receptors: pharmacol- ogical, properties, species differences and receptor functions. Trends Pharmacol. Sci. (1994) 15 (8) :298–306.
- •Useful background review.
- JACOBSON KA: Adenosine A3 receptors: novel ligands and, paradoxical effects. Trends Pharmacol ScL (1998) 19(5) :184–91.
- ••Good review by a leading expert on adenosine receptors.
- REEVES JJ, JONES CA, SHEEHAN MJ, VARDEY CJ, WHELAN CJ,: Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm. Res. (1997) 46(5):180–4.
- EZEAMUZIE CI, PHILIPS E Adenosine A3 receptors on human, eosinophils mediate inhibition of degranulation, and superoxide anion release. Br. J. Pharmacol. (1999) 127(0:188–194.
- FOZARD JR, HANNON JP: Adenosine receptor ligands: potential, as therapeutic agents in asthma and COPD. Pulm. Pharmacol. Ther. (1999) 12 (2) :111–114.
- ••The background put by Novartis' former head of respiratoryR&D.
- LEVENS N, BEIL M, SCHULZ R: Intrarenal actions of the new adenosine agonist CGS 21680A, selective for the A2 receptor. J. Pharmacol. Exp. Ther. (1 9 9 1) 2 5 7(3):1013–1019.
- GHAI G, FRANCIS JE, WILLIAMS M et al.: Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. J. Pharmacol. Exp. Ther. (1987) 242(3)784–790.
- BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Exp. Opin. Ther. Patents (2000) 10(0:25–38.
- LE-VRAUX V, CHEN Y L, MASSON I, DE-SOUSA M et al: Inhibition of human TNF production by adenosine receptor agonists. Life ScL (1993) 52:1917–1924.